Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 6/2011

01-12-2011 | Review Article

Diseases of the parathyroid gland in chronic kidney disease

Authors: Hirotaka Komaba, Takatoshi Kakuta, Masafumi Fukagawa

Published in: Clinical and Experimental Nephrology | Issue 6/2011

Login to get access

Abstract

During the past few years, remarkable advances have been made in the understanding and the management of parathyroid diseases in patients with chronic kidney disease (CKD). One of the important insights is the identification of fibroblastic growth factor 23, which has greatly reshaped our understanding of secondary hyperparathyroidism (SHPT). The recent introduction of calcimimetic cinacalcet hydrochloride has led to a major breakthrough in the management of SHPT. Recognition of circulating molecular forms of parathyroid hormone (PTH) is also a major milestone in the accurate assessment of parathyroid function in CKD. Primary hyperparathyroidism should also be considered in patients with CKD, because it can cause various renal manifestations and can also occur as a sporadic disease in these patients. Hypoparathyroidism is occasionally seen in dialysis patients in the setting of diabetes mellitus and malnutrition–inflammation complex syndrome, as well as after parathyroidectomy for advanced SHPT. For patients with adynamic bone disease due to hypoparathyroidism and/or skeletal resistance to PTH, teriparatide, a PTH analog, may have potential for improving bone metabolism and reducing the risk of fracture. In this review, we summarize our current knowledge on diseases of the parathyroid gland in CKD patients, with a particular focus on recent work in the field.
Literature
1.
2.
Brown EM, Pollak M, Seidman CE, Seidman JG, Chou YH, Riccardi D, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med. 1995;333:234–40.PubMedCrossRef
3.
4.
5.
Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118:3820–8.PubMedCrossRef
6.
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006;281:6120–3.PubMedCrossRef
7.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–4.PubMedCrossRef
8.
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003–8.PubMed
9.
Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125–31.PubMedCrossRef
10.
Drüeke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol. 2000;11:1141–52.PubMed
11.
Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int. 2006;70(Suppl 102):S3–7.CrossRef
12.
Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J Nephrol. 2011;33:427–37.PubMedCrossRef
13.
Fukagawa M, Nakanishi S, Fujii H, Hamada Y, Abe T. Regulation of parathyroid function in chronic kidney disease. Clin Exp Nephrol. 2006;10:175–9.PubMedCrossRef
14.
Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis. 1995;25:663–79.PubMedCrossRef
15.
Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996;11(Suppl 3):130–5.PubMed
16.
Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496–502.PubMedCrossRef
17.
Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010;77:292–8.PubMedCrossRef
18.
Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21:1427–35.PubMedCrossRef
19.
Gutiérrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the “trade-off” hypothesis. Clin J Am Soc Nephrol. 2010;5:1710–6.PubMedCrossRef
20.
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–35.PubMedCrossRef
21.
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500–5.PubMedCrossRef
22.
Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250–6.PubMedCrossRef
23.
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–15.PubMedCrossRef
24.
Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005;67:1171–8.PubMedCrossRef
25.
Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2005;101:c94–9.PubMedCrossRef
26.
Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–8.PubMedCrossRef
27.
Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78:975–80.PubMedCrossRef
28.
Naveh-Many T, Nechama M. Regulation of parathyroid hormone mRNA stability by calcium, phosphate and uremia. Curr Opin Nephrol Hypertens. 2007;16:305–10.PubMedCrossRef
29.
Nechama M, Uchida T, Mor Yosef-Levi I, Silver J, Naveh-Many T. The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J Clin Invest. 2009;119:3102–14.PubMedCrossRef
30.
Wang Q, Palnitkar S, Parfitt AM. The basal rate of cell proliferation in normal human parathyroid tissue: Implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol. 1997;46:343–9.CrossRef
31.
Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:78–86.PubMedCrossRef
32.
Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436–43.PubMedCrossRef
33.
Kifor O, Moore FD Jr, Wang P, Goldstein M, Vassilev P, Kifor I, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598–606.PubMedCrossRef
34.
Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328–36.PubMedCrossRef
35.
Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58:1980–6.PubMedCrossRef
36.
Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002;62:1196–207.PubMedCrossRef
37.
Cozzolino M, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol. 2005;289:F1096–102.PubMedCrossRef
38.
Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol. 2008;19:310–20.PubMedCrossRef
39.
Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010;77:232–8.PubMedCrossRef
40.
Kumata C, Mizobuchi M, Ogata H, Koiwa F, Nakazawa A, Kondo F, et al. Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol. 2010;31:230–8.PubMedCrossRef
41.
Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77:211–8.PubMedCrossRef
42.
Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010;21:1125–35.PubMedCrossRef
43.
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in endstage renal failure—an evolving disorder. Kidney Int. 1993;43:436–42.PubMedCrossRef
44.
Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, et al. Aplastic osteodystrophy without aluminium: the role of ‘suppressed’ parathyroid function. Kidney Int. 1993;44:860–6.PubMedCrossRef
45.
Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis. 1995;26:836–44.PubMedCrossRef
46.
Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 2010;77:93–100.PubMedCrossRef
47.
48.
Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. Clin Endocrinol Metab. 1968;28:1037–47.CrossRef
49.
Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33:1364–7.PubMed
50.
Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D’Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81:3923–9.PubMedCrossRef
51.
Divieti P, John MR, Jüppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology. 2002;143:171–6.PubMedCrossRef
52.
D’Amour P. Circulating PTH molecular forms: what we know and what we don’t. Kidney Int. 2006;70(Suppl 102):S29–33.CrossRef
53.
John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not aminoterminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab. 1999;84:4287–90.PubMedCrossRef
54.
Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Intermethod variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345–50.PubMedCrossRef
55.
Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008;51:987–95.PubMedCrossRef
56.
Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, et al. Improved assessment of bone turnover by the PTH-(1-84) large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460–8.PubMedCrossRef
57.
Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, et al. PTH 1-84 and PTH “7-84” in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40:348–54.PubMedCrossRef
58.
Lehmann G, Stein G, Hüller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68:1206–14.PubMedCrossRef
59.
Tanaka H, Komaba H, Koizumi M, Kakuta T, Fukagawa M. Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism. Ther Apher Dial. 2011;15(Suppl 1):56–61.PubMedCrossRef
60.
Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor TL, Kurosawa T, et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis. 2001;38(Suppl 1):S172–4.PubMedCrossRef
61.
Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, et al. Technical and clinical characterization of the Bio-PTH(1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem. 2004;50:385–90.PubMedCrossRef
62.
Arakawa T, D’Amour P, Rousseau L, Brossard JH, Sakai M, Kasumoto H, et al. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol. 2006;1:525–31.PubMedCrossRef
63.
Tanaka M, Itoh K, Matsushita K, Matsushita K, Fujii H, Fukagawa M. Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin Nephrol. 2005;64:69–72.PubMed
64.
Komaba H, Takeda Y, Abe T, Komaba K, Otsuki N, Nibu K, et al. Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH/intact PTH ratio in a haemodialysis patient. Nephrol Dial Transplant. 2008;23:1760–2.PubMedCrossRef
65.
Komaba H, Takeda Y, Shin J, Tanaka R, Kakuta R, Tominaga Y, et al. Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review. NDT Plus. 2008;1(Suppl 3):iii54–8.CrossRef
66.
Komaba H, Shin J, Fukagawa M. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. Nephrol Dial Transplant. 2010;25:638–41.PubMedCrossRef
67.
D’Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem. 2003;49:2037–44.PubMedCrossRef
68.
Räkel A, Brossard JH, Patenaude JV, Albert C, Nassif E, Cantor T, et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol. 2005;62:721–7.CrossRef
69.
Rubin MR, Silverberg SJ, D’Amour P, Brossard JH, Rousseau L, Sliney J Jr, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470–6.PubMedCrossRef
70.
Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii PN, Delanaye P, Stubbs P, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab. 2010;95:3745–9.PubMedCrossRef
71.
Tanaka M, Komaba H, Itoh K, Matsushita K, Matshushita K, Hamada Y, et al. The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. NDT Plus. 2008;1(Suppl 3):iii59–62.CrossRef
72.
73.
Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70:1358–66.PubMedCrossRef
74.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.PubMedCrossRef
75.
Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119–27.PubMedCrossRef
76.
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–53.PubMedCrossRef
77.
Disease Kidney, Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1–130.
78.
Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009;4:178–85.PubMedCrossRef
79.
Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD–MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–91.PubMedCrossRef
80.
Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362:1312–24.PubMedCrossRef
81.
Carrillo-López N, Fernández-Martín JL, Alvarez-Hernández D, González-Suárez I, Castro-Santos P, Román-García P, et al. Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. Nephrol Dial Transplant. 2010;25:2930–7.PubMedCrossRef
82.
Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest. 1984;74:2136–43.PubMedCrossRef
83.
Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis. 2001;38(Suppl 5):S45–50.PubMedCrossRef
84.
Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, et al. Long-term effect of 1, 25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant. 2002;17(Suppl 10):28–36.PubMed
85.
Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994;68:221–8.PubMedCrossRef
86.
Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2003;18:2613–21.PubMedCrossRef
87.
Tominaga Y, Inaguma D, Matsuoka S, Tahara H, Kukita K, Kurihara S, et al. Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial. 2006;10:198–204.PubMedCrossRef
88.
Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179–84.PubMedCrossRef
89.
Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115–25.PubMedCrossRef
90.
Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–13.PubMedCrossRef
91.
Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant. 2008;23:3670–6.PubMedCrossRef
92.
Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006;70:654–9.PubMedCrossRef
93.
Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1529–39.PubMedCrossRef
94.
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–25.PubMedCrossRef
95.
Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23:328–35.PubMedCrossRef
96.
Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36–45.PubMedCrossRef
97.
Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008;3:1718–25.PubMedCrossRef
98.
Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2:898–905.PubMedCrossRef
99.
Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5:2305–14.PubMedCrossRef
100.
Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol. 2000;11:903–11.PubMed
101.
Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004;15:2579–87.PubMedCrossRef
102.
Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:87–96.PubMedCrossRef
103.
Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66:2010–6.PubMedCrossRef
104.
Trombetti A, Stoermann C, Robert JH, Herrmann FR, Pennisi P, Martin PY, et al. Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Surg. 2007;31:1014–21.PubMedCrossRef
105.
Costa-Hong V, Jorgetti V, Gowdak LH, Moyses RM, Krieger EM, De Lima JJ. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery. 2007;142:699–703.PubMedCrossRef
106.
Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol. 2007;18:2401–7.PubMedCrossRef
107.
Tominaga Y, Katayama A, Sato T, Matsuoka S, Goto N, Haba T, et al. Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant. 2003;18(Suppl 3):iii65–70.PubMed
108.
Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int. 1994;46:1110–7.PubMedCrossRef
109.
Shiizaki K, Hatamura I, Negi S, Narukawa N, Mizobuchi M, Sakaguchi T, et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int. 2003;64:992–1003.PubMedCrossRef
110.
Koiwa F, Kakuta T, Tanaka R, Yumita S. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2007;22:522–8.PubMedCrossRef
111.
Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171–7.PubMedCrossRef
112.
Ruda JM, Hollenbeak CS, Stack BC Jr, et al. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359–72.PubMedCrossRef
113.
Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med. 1990;323:1324–8.PubMedCrossRef
114.
VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab. 2006;91:580–3.PubMedCrossRef
115.
Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore). 1974;53:127–46.
116.
Bilezikian JP, Potts JT Jr. Asymptomatic primary hyperparathyroidism: new issues and new questions—bridging the past with the future. J Bone Miner Res. 2002;17(Suppl 2):N57–67.PubMed
117.
Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med. 2004;350:1746–51.PubMedCrossRef
118.
Bilezikian JP, Khan AA, Potts JT Jr. Summary statement: guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94:335–9.PubMedCrossRef
119.
Mizumoto D, Watanabe Y, Fukuzawa Y, Aoi N, Yamazaki C. Clinical profile and outcome of primary hyperparathyroidism accompanied by chronic renal failure. Clin Nephrol. 1994;42:315–21.PubMed
120.
Jimbo-Saito R, Ubara Y, Kadoguchi H, Suwabe T, Nakanishi S, Higa Y, et al. A case of primary hyperparathyroidism with severe bone and renal changes. J Bone Miner Metab. 2009;27:727–32.PubMedCrossRef
121.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–8.PubMedCrossRef
122.
Tominaga Y, Uchida K, Haba T, Katayama A, Sato T, Hibi Y, et al. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis. 2001;38(4 Suppl 1):S168–71.PubMedCrossRef
123.
Au AY, McDonald K, Gill A, Sywak M, Diamond T, Conigrave AD, et al. PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med. 2008;359:1184–6.PubMedCrossRef
124.
Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249–55.PubMedCrossRef
125.
Abdelhadi M, Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab. 1998;83:3845–51.PubMedCrossRef
126.
Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598–602.PubMedCrossRef
127.
Mollerup CL, Vestergaard P, Frøkjaer VG, Mosekilde L, Christiansen P, Blichert-Toft M, et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ. 2002;325(7368):807.PubMedCrossRef
128.
Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235:665–70.PubMedCrossRef
129.
Carling T, Donovan P, Rinder C, Udelsman R. Minimally invasive parathyroidectomy using cervical block: reasons for conversion to general anesthesia. Arch Surg. 2006;141:401–4.PubMedCrossRef
130.
Irvin GL III, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg. 2004;28:1287–92.PubMedCrossRef
131.
Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16:113–9.PubMedCrossRef
132.
Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:581–7.PubMedCrossRef
133.
Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319–25.PubMedCrossRef
134.
Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174–8.PubMedCrossRef
135.
Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:5644–9.PubMedCrossRef
136.
Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135–41.PubMedCrossRef
137.
Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2766–72.PubMedCrossRef
138.
D’Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, et al. Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery. 1989;106:1049–55.PubMed
139.
Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant. 2005;5:1934–41.PubMedCrossRef
140.
Hernández D, Rufino M, Bartolomei S, González-Rinne A, Lorenzo V, Cobo M, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int. 2005;67:2015–20.PubMedCrossRef
141.
Taniguchi M, Tokumoto M, Matsuo D, Motoyama K, Sugitani A, Kuroki S, et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70:363–70.PubMedCrossRef
142.
Levi M. Post-transplant hypophosphatemia. Kidney Int. 2001;59:2377–87.PubMed
143.
Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, et al. Post-transplant hypophosphatemia: tertiary ‘hyper-phosphatoninism’? Kidney Int. 2006;70:1486–94.PubMedCrossRef
144.
Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Nakajima I, Fuchinoue S, et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant (in press).
145.
Evenepoel P, Meijers BK, de Jonge H, Naesens M, Bammens B, Claes K, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3:1829–36.PubMedCrossRef
146.
Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:323–6.PubMedCrossRef
147.
Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007;22:577–83.PubMedCrossRef
148.
Sugimoto T, Ritter C, Morrissey J. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990;37:1522–7.PubMedCrossRef
149.
Murakami R, Murakami S, Tsushima R, Ueda C, Mikami K, Ebina T, et al. Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy. Nephrol Dial Transplant. 2008;23:315–20.PubMedCrossRef
150.
Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, et al. Association of relatively low serum parathyroid hormone with malnutrition–inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010;20:243–54.PubMedCrossRef
151.
Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens. 2000;9:363–7.PubMedCrossRef
152.
Brandenburg VM, Floege J. Adynamic bone disease—bone and beyond. NDT Plus. 2008;1:135–47.CrossRef
153.
Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, et al. Insufficiency of PTH action on bone in uremia. Kidney Int. 2006;70(Suppl 102):S34–6.CrossRef
154.
Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58:753–61.PubMed
155.
Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000;58:1440–9.
156.
Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant. 2005;20:1904–11.PubMedCrossRef
157.
Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002;39:525–32.PubMedCrossRef
158.
Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant. 2006;21:2768–74.PubMedCrossRef
159.
Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int. 2007;71:738–43.PubMedCrossRef
160.
Jamal SA, Hodsman AB. Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues? Semin Dial. 2011;24:12–5.PubMedCrossRef
161.
Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH(1-34)): a pilot study. Kidney Blood Press Res. 2010;33:221–6.PubMedCrossRef
162.
Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000;105:1595–604.PubMedCrossRef
Metadata
Title
Diseases of the parathyroid gland in chronic kidney disease
Authors
Hirotaka Komaba
Takatoshi Kakuta
Masafumi Fukagawa
Publication date
01-12-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0502-5

Other articles of this Issue 6/2011

Clinical and Experimental Nephrology 6/2011 Go to the issue

Original Article

Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients

Letter to the Editor

Necrotizing crescentic immunoglobulin A glomerulonephritis in adult-onset Still’s disease

Case Report

A large-sized bubbling appearance of the glomerular basement membrane in a patient with pulmonary limited AL amyloidosis and a past history of lupus nephritis

Acknowledgment

List of referees

Original Article

Validation of the equations for estimating daily sodium excretion from spot urine in patients with chronic kidney disease

Original Article

Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits